Thierry Olivry, Lucie Mirande, Lorenz Aglas, Bertrand Morel, Ana Mas-Fontao, Anne-Catherine Fitchette, Lena Holztrattner, Maria Stigler, Joannie Roberge, Caroline Martel, Virginie Stordeur, Réjean Desgagnés, Louis Vézina, Claude Favrot, Véronique Gomord
{"title":"Rapid induction of allergen-blocking IgG in dogs vaccinated with plant-based, Der f 2-expressing bioparticles.","authors":"Thierry Olivry, Lucie Mirande, Lorenz Aglas, Bertrand Morel, Ana Mas-Fontao, Anne-Catherine Fitchette, Lena Holztrattner, Maria Stigler, Joannie Roberge, Caroline Martel, Virginie Stordeur, Réjean Desgagnés, Louis Vézina, Claude Favrot, Véronique Gomord","doi":"10.1111/vde.13291","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allergen-carrying virus-like particles are effective and safe means of allergen immunotherapy (AIT) in rodent models.</p><p><strong>Objective: </strong>To study the development of allergen-blocking immunoglobulin (Ig)G in dogs injected with Der f 2-carrying enveloped plant-based bioparticles (eBPs).</p><p><strong>Materials and methods: </strong>Laboratory beagle dogs were injected intradermally (ID) or subcutaneously (SC) with Der f 2-eBP three times at 2-week intervals. A basophil mediator release assay was used to compare the reactivity of Der f 2-eBPs to that of recombinant Der f 2. Allergen-specific IgG serum levels were determined by immunoblotting and ELISA. The allergen-blocking potential of postvaccination IgG was assessed by Pet Allergy Xplorer (PAX) macroarray and basophil mediator release inhibition assays.</p><p><strong>Results: </strong>The amount of Der f 2 eBPs needed to induce basophil activation was 1000-fold higher than that of the soluble natural allergen. In both immunisation groups, eBP injections caused no adverse events and induced Der f 2-specific IgG, first detected on Day (D)14 and peaking on D41. The co-incubation of sera with a Der f 2-IgE-rich canine serum pool resulted in a mean PAX inhibition of 70% (ID) to 80% (SC) on D41. For both groups, the inhibition of basophil mediator release reached 75% on D28 and D41. The percentage inhibition of PAX and mediator release correlated significantly with Der f 2 IgG levels.</p><p><strong>Conclusion and clinical relevance: </strong>Intradermal and subcutaneous injections of Der f 2-eBPs were safe and increased Der f 2-specific IgG. The clinical benefit of immunotherapy will be evaluated in future trials enrolling atopic dogs allergic to house dust mites.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":" ","pages":"672-682"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary dermatology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/vde.13291","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Allergen-carrying virus-like particles are effective and safe means of allergen immunotherapy (AIT) in rodent models.
Objective: To study the development of allergen-blocking immunoglobulin (Ig)G in dogs injected with Der f 2-carrying enveloped plant-based bioparticles (eBPs).
Materials and methods: Laboratory beagle dogs were injected intradermally (ID) or subcutaneously (SC) with Der f 2-eBP three times at 2-week intervals. A basophil mediator release assay was used to compare the reactivity of Der f 2-eBPs to that of recombinant Der f 2. Allergen-specific IgG serum levels were determined by immunoblotting and ELISA. The allergen-blocking potential of postvaccination IgG was assessed by Pet Allergy Xplorer (PAX) macroarray and basophil mediator release inhibition assays.
Results: The amount of Der f 2 eBPs needed to induce basophil activation was 1000-fold higher than that of the soluble natural allergen. In both immunisation groups, eBP injections caused no adverse events and induced Der f 2-specific IgG, first detected on Day (D)14 and peaking on D41. The co-incubation of sera with a Der f 2-IgE-rich canine serum pool resulted in a mean PAX inhibition of 70% (ID) to 80% (SC) on D41. For both groups, the inhibition of basophil mediator release reached 75% on D28 and D41. The percentage inhibition of PAX and mediator release correlated significantly with Der f 2 IgG levels.
Conclusion and clinical relevance: Intradermal and subcutaneous injections of Der f 2-eBPs were safe and increased Der f 2-specific IgG. The clinical benefit of immunotherapy will be evaluated in future trials enrolling atopic dogs allergic to house dust mites.
背景:携带过敏原的病毒样颗粒是啮齿动物模型中有效、安全的过敏原免疫疗法(AIT)手段:携带过敏原的病毒样颗粒是在啮齿类动物模型中进行过敏原免疫疗法(AIT)的有效而安全的手段:研究狗注射携带Der f 2的包膜植物基生物颗粒(eBPs)后过敏原阻断免疫球蛋白(Ig)G的发育情况:给实验用小猎犬皮内(ID)或皮下(SC)注射 Der f 2-eBP 三次,每次间隔 2 周。通过免疫印迹法和酶联免疫吸附法测定过敏原特异性 IgG 血清水平。宠物过敏 Xplorer (PAX) 宏阵列和嗜碱性粒细胞介质释放抑制试验评估了接种后 IgG 的过敏原阻断潜力:结果:诱导嗜碱性粒细胞活化所需的 Der f 2 eBPs 量是可溶性天然过敏原量的 1000 倍。在两个免疫组中,注射 eBP 均未引起不良反应,并能诱导 Der f 2 特异性 IgG,在第 14 天首次检测到,在第 41 天达到高峰。血清与富含 Der f 2-IgE 的犬血清池共同孵育后,D41 日的平均 PAX 抑制率为 70%(ID)至 80%(SC)。两组对嗜碱性粒细胞介质释放的抑制率在 D28 和 D41 均达到 75%。对 PAX 和介质释放的抑制百分比与 Der f 2 IgG 水平显著相关:皮内和皮下注射 Der f 2-eBPs 是安全的,并能增加 Der f 2 特异性 IgG。免疫疗法的临床疗效将在今后对过敏性犬只进行的试验中进行评估。
期刊介绍:
Veterinary Dermatology is a bi-monthly, peer-reviewed, international journal which publishes papers on all aspects of the skin of mammals, birds, reptiles, amphibians and fish. Scientific research papers, clinical case reports and reviews covering the following aspects of dermatology will be considered for publication:
-Skin structure (anatomy, histology, ultrastructure)
-Skin function (physiology, biochemistry, pharmacology, immunology, genetics)
-Skin microbiology and parasitology
-Dermatopathology
-Pathogenesis, diagnosis and treatment of skin diseases
-New disease entities